Skip to content
Clinical Trials – home

Azienda Ospedaliero Universitaria Ospedali Riuniti

Verified siteinfo

Italy Viale Luigi Pinto 1, 71122 Foggia, Italy

  • 57 trials recruiting
  • Idiopathic pulmonary fibrosis · Metabolic dysfunction-associated steatohepatitis · Hormone-refractory prostate cancer
  • Adults and children

About Specializations

Azienda Ospedaliero Universitaria Ospedali Riuniti in Foggia, Italy specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Metabolic dysfunction-associated steatohepatitis, Hormone-refractory prostate cancer, Multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory and Lung Disease Research

Clinical trials at Azienda Ospedaliero Universitaria Ospedali Riuniti include a strong focus on respiratory tract diseases, especially asthma and idiopathic pulmonary fibrosis. These studies are designed to explore new ways to ease symptoms, reduce flare-ups, and improve day-to-day breathing for people living with chronic lung conditions.

  • Testing new treatment options for asthma control and fewer exacerbations
  • Evaluating therapies aimed at relieving cough in idiopathic pulmonary fibrosis
  • Studying better symptom management for chronic respiratory disease

The site’s respiratory department supports research that may help improve both treatment effectiveness and quality of life for patients with long-term lung disease.

Liver, Metabolic, and Digestive Health Studies

A notable part of the research portfolio centers on digestive system diseases and nutritional and metabolic diseases, with studies in non-alcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, and related fibrosis. This work aims to better understand liver inflammation and scarring while assessing new therapies for patients with progressive metabolic liver disease.

  • Investigating treatments for NASH and MASH with fibrosis
  • Assessing safety and tolerability of emerging liver-directed therapies
  • Exploring ways to slow disease progression and improve liver outcomes

These trials reflect an active effort to advance care for patients at risk of serious liver complications, including long-term damage and liver failure.

Cardiovascular and Stroke Prevention Research

The site is also involved in cardiovascular diseases research, including studies in heart failure with preserved or mildly reduced ejection fraction and atrial fibrillation to help prevent stroke and systemic embolism. These trials are focused on improving protection against major cardiovascular events while balancing treatment safety.

  • Evaluating new approaches for heart failure with inflammation
  • Studying therapies to reduce stroke risk in atrial fibrillation
  • Comparing treatment options for better cardiovascular benefit and safety

Research in this area may support more effective long-term management for patients with complex heart and circulation problems.

Oncology and Advanced Cancer Treatment

Neoplasms are another important research area at this hospital, with trials in prostate cancer and advanced biliary tract cancers. The studies are examining new treatment combinations and strategies to improve cancer control in patients with advanced or resistant disease.

  • Testing combination treatments for advanced biliary tract cancers
  • Studying therapy options for metastatic prostate cancer
  • Exploring approaches for patients whose cancer has progressed after prior treatment

This oncology research is aimed at improving response rates, extending disease control, and offering better options for patients with difficult-to-treat cancers.

Infectious Disease and HIV Research

The clinical trial program includes virus diseases research, particularly HIV-1 infection. These studies focus on treatment strategies that may help people achieve viral suppression more quickly and maintain control over the infection with simpler long-term care.

  • Evaluating treatment approaches for adults starting HIV therapy
  • Studying long-term maintenance of viral suppression
  • Assessing patient-friendly regimens for ongoing HIV management

Such trials support ongoing progress toward more convenient and effective HIV care.

Neurology, Psychiatry, and Neurodevelopmental Research

Research at the site also covers nervous system diseases and mental disorders, including autism spectrum disorders. These studies are designed to improve understanding of social communication challenges and to test new options that may support behavioral and developmental outcomes.

  • Studying therapies for core social communication difficulties in autism
  • Exploring interventions that may improve behavior and daily functioning
  • Advancing care in neurodevelopmental and mental health conditions

This area highlights the site’s interest in research that may help patients across childhood and adult neuropsychiatric care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Viale Luigi Pinto 171122 FoggiaItaly
Recruiting now
57 trials
Conditions studied
73
Partner status
Verified site

More sites in FoggiaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

121 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.